Multiple Antibody Targets on Herpes B Glycoproteins B and D Identified by Screening Sera of Infected Rhesus Macaques with Peptide Microarrays

Sven-Kevin Hotop1,2, Ahmed Abd El Wahed2,3, Ulrike Beutling2, Dieter Jentsch1, Dirk Motzkus1, Ronald Frank3, Gerhard Hunsmann2, Christiane Stahl-Hennig1,*, Hans-Joachim Fritz4

1 Unit of Infection Models, German Primate Center, Göttingen, Germany, 2 Department of Virology, University Medical Center, Georg-August University Göttingen, Göttingen, Germany, 3 Department of Chemical Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany, 4 Courant Research Centre Geobiology, Göttingen, Germany

Abstract

Herpes B virus (or Herpesvirus simiae or Macacine herpesvirus 1) is endemic in many populations of macaques, both in the wild and in captivity. The virus elicits only mild clinical symptoms (if any) in monkeys, but can be transmitted by various routes, most commonly via bites, to humans where it causes viral encephalitis with a high mortality rate. Hence, herpes B constitutes a considerable occupational hazard for animal caretakers, veterinarians and laboratory personnel. Efforts are therefore being made to reduce the risk of zoonotic infection and to improve prognosis after accidental exposure. Among the measures envisaged are serological surveillance of monkey colonies and specific diagnosis of herpes B zoondosis against a background of antibodies recognizing the closely related human herpes simplex virus (HSV). 422 pentadecapeptides covering, in an overlapping fashion, the entire amino acid sequences of herpes B proteins gB and gD were synthesized and immobilized on glass slides. Antibodies present in monkey sera that bind to subsets of the peptide collection were detected by microserological techniques. With 42 different rhesus macaque sera, 114 individual responses to 18 different antibody target regions (ATRs) were recorded, 17 of which had not been described earlier. This finding may pave the way for a peptide-based, herpes B specific serological diagnostic test.

Introduction

Herpes B was first described as a human case of acute ascending myelitis with lethal outcome, following a monkey bite; a filterable transmitting agent ("B virus", later named herpes B virus) could be recovered post mortem from various tissues of the victim [1]. Herpes B belongs to the genus Simplexvirus within the Alphaherpesvirinae subfamily of the Herpesviridae family. The enveloped particle harbors a linear double-stranded DNA genome of approximately 157 kb [2–4]. The genomes of herpes B and human herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are made up to a great extent by homologous genes in the same order and orientation [4]. This similarity at the level of genome organization is reflected by an average of approximately 62% identity of amino acid residues across all homologous proteins herpes B shares with both HSV-1 and HSV-2 [2]. The viral envelope contains twelve glycoproteins, among them four with proven high immunogenicity: gB, gC, gD and mgG [4,5].

Establishment and sustainable maintenance of specific pathogen-free monkey colonies depends on reliable identification of carrier animals [6]. With herpes B, this cannot be achieved by testing body fluids for virus-specific nucleic acids, due to long periods of latency during which the viral genome only persists in sensory ganglia but no virions are shed to the periphery [4]. Thus, serological identification of anti-herpes B antibodies is the only way to discover infected animals. Several serological techniques relying on recombinant proteins and cell lysates of herpes B are currently in use to detect this viral infection [5]. In addition, a commercially available herpes simplex virus (HSV) ELISA has been employed because of cross-reactivity [7]. By using this assay, however, differences in primary sequences could lead to "false negative" results which must be prevented for safety reasons. For this purpose, mapping anti-herpes B antibody targets may be a valuable tool to improve herpes B diagnosis. To date, only one epitope has been described at the C-terminal end of gD [8]. Whether or not other epitopes exist has been unknown until now.

To elucidate the spatial distribution of BV epitopes we have developed and applied a peptide microarray covering the whole amino acid sequences of the structural proteins gB and gD. Using this high throughput platform we have identified seventeen novel linear epitopes in addition to the one that was previously described [8]. The study provides evidence that profiling of sera at single
epitope resolution is a powerful tool to comprehensively describe individual B cell responses that could significantly improve current diagnostics.

Materials and Methods

For the collection of samples for diagnostic purposes, we did not need an IACUC approval because this was not related to any experimental procedure but was linked to animal care. However, the German Primate Center has the permission to breed and keep nonhuman primates (as stated in the paragraph below) which includes animal health monitoring and sampling for diagnostic purposes.

Origin of Monkey Sera, Ethics Statement and Animal Care

Thirty-six test sera used in this study were derived from blood samples collected by experienced veterinarians from rhesus macaques (Macaca mulatta) as part of the breeding colony at the German Primate Center (DPZ). Sampling was conducted within the framework of the annual animal health monitoring for a variety of veterinary diagnostics. For the collection of the blood samples animals were anesthetized intra-muscularly with 10–15 mg ketamine per kg body weight; none of the animals were euthanized. The samples were cryopreserved as part of the routine sample banking of the Unit of Animal Husbandry at the DPZ. According to §11 of the German Animal Welfare Act, the DPZ has permission to breed and house nonhuman primates under license number 392001/7 issued by the local veterinary authorities. Animals were cared for by trained staff at the DPZ in accordance with institutional guidelines based on the German Animal Welfare Act. This comprises supervision and advice by the institutional animal welfare officer. The animals were housed under conditions as stipulated in the European Directive 2010/63/EU (directive on the protection of animals used for experimental and other scientific purposes) and the EU Recommendations 2007/526/EG (guidelines for the accommodation and care of animals used for experimental and other scientific purposes) which are in line with the NRC (USA) Guide for the Care and Use of Laboratory Animals. The macaques had access to indoor (43 m² and a height of 7 m, room temperature 18–20°C) and outdoor areas (a height of 7 m and floor space of 370 m² with a natural surface), equipped with wooden climbing gadgets, swings, ropes and chains, fire hoses, car tires, barrels and water basins. Meals were supplied three times a day in different compositions where the basic food supply consists of dry monkey biscuits and protein-enriched mash supplemented with fresh fruits and vegetables and additional edible items (e.g. seeds, cereals, nuts). Fresh water was provided ad libitum.

Reference Sera

Three anti-herpes B positive reference sera and three negative ones were kindly provided by the National B Virus Resource Laboratory, Atlanta, GA, USA. The positive monkey sera were derived from naturally infected rhesus macaques. The reference sera had been identified as positive/negative by an ELISA based on whole lysed herpes B antigen reaching titers of around 1:10,000. The positive responses were confirmed by Western Blot and second ELISA in which gB, gC, gD and mgG, produced by genetic engineering, were used for coating (M.J. Wildes, personal communication).

Peptide Microarray

Herpes B scanning chips, based on gB and gD of herpes B, strain E2490 (GenBank accession number AF533768), were used for screening the monkey sera. Peptides were synthesized as

Figure 1. Peptide microarray layout. (A) Each chip contains eight arrays (I–VIII) with identical peptide sequence and layout. Peptides were printed at three different amounts per spot, 360 fmol (I and II), 180 fmol (III–VII), and 90 fmol (VII and VIII). For orientation, each array is bordered by marker spots (biotin) that give rise to green fluorescent signals upon screening. (B) The upper part of each array consists of 294 15mers corresponding to the amino acid sequence of gB, each overlapping by 12 amino acid residues. The lower part is printed with peptides corresponding to the sequence of gD with the same specifications for gB. The empty space between the gB and gD peptides was used for spotting of process control peptides (1D3). (C) Amino acid sequence of the first three peptides covering gB, corresponding to spots #1–#3 in (B). doi:10.1371/journal.pone.0086857.g001
Data Acquisition

The chip was washed with 98% [v/v] ethanol for 3 min and then three times with Tris-buffered saline (TBS: 240 mM Tris/HCl, 1.5 mM KCl, 470 mM NaCl, pH 7.0) for 3 min each. After incubation with blocking buffer (2% [w/v] casein in T-TBS: TBS, 0.05% [w/v] Tween 20) at room temperature for one hour, the chip was washed once with T-TBS for 3 min. Thereafter, 60 µl of serum sample (1:60 in blocking buffer) was loaded onto the chip. The chip was incubated in a humidified chamber at 4°C overnight. Thereafter, the chip was washed three times for 5 min each with T-TBS. To visualize bound antibodies and biotin spots, 60 µl of blocking buffer containing monkey IgG cross-reactive Cy3-conjugated goat anti-human IgG and Cy3-conjugated mouse anti-biotin antibody (Jackson ImmunoResearch, USA) were added to the chip at optimal dilutions. The chip was kept in the above-mentioned chamber at room temperature for 1.5 hours. Subsequently, the chip was washed twice for 5 min each with T-TBS, three times with distilled water for 5 min each, and dried in a stream of compressed air. The distribution of fluorescence intensities across the chip was determined using a DNA microarray scanner (Agilent Technologies, USA). Enrichment of IgG antibodies was done with a protein A IgG purification kit according to the manufacturer’s instructions (Fierce Biotechnology, Rockford, USA).

Algorithm for Semi-automated Spot Calling

Experimentally obtained fluorescence patterns were displayed using Agilent Feature Extraction program, Version 7.5 (Agilent Technologies, USA) in standard settings and saved as a bitmap containing 8-bit of brightness information per pixel for each of the three color channels. Bitmaps (without separation of colors) were manually aligned (tilt angle, x/y-translation) with a pre-defined grid of adjoining squares using CorelDRAW X5 software (Corel Inc., USA) such that, in accord with the spot layout of the chip and the resolution of the chip reader, each square had a size of 20×20 pixels and housed a single spot. Subsequently, readings of red and green fluorescence (test and marker spots, respectively) were separated using ImageJ software [11]. For numerical processing of test spot readings, all corresponding sets of 400 numbers were summed up individually and the resulting values were exported to Excel (Microsoft, version 2010). For each individual array (eight per chip, see Figure 1), the mean of all cell readings was computed manually aligned (tilt angle, x/y-translation) with a pre-defined grid of adjoining squares using CorelDRAW X5 software (Corel Inc., USA) such that, in accord with the spot layout of the chip and the resolution of the chip reader, each square had a size of 20×20 pixels and housed a single spot. Subsequently, readings of red and green fluorescence (test and marker spots, respectively) were separated using ImageJ software [11]. For numerical processing of test spot readings, all corresponding sets of 400 numbers were summed up individually and the resulting values were exported to Excel (Microsoft, version 2010). For each individual array (eight per chip, see Figure 1), the mean of all cell readings was computed and spots with values above that average were discarded as potential positive values. From the remaining subset, a second average was calculated and a final cut-off was defined as the second average plus one standard deviation. Spots in the “above cut-off” class were defined as a positive response if they were above the threshold in at least six out of eight arrays.

HSV-ELISA

An anti-herpes simplex virus ELISA (Enzygnost Anti-HSV/IgG Test Kit, DADE Chiron, Germany), known to be cross-reactive with herpes B antibodies [7], was used according to the manufacturer’s instructions with the following modification: a conjugate of goat anti-human IgG (H+L) and horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA, USA) was employed because, in our hands, its sensitivity and performance proved superior to both the immunon conjugate included in the original kit and the one based on an anti-(simian) IgG antibody described earlier [7].

Results

Peptide Microarray Assay Design

With the aim of serologically profiling macaque sera for footprints of herpes B antigens at single epitope resolution, peptide microarrays based on the highly immunogenic proteins gB and gD [5,12] were prepared as described [9,10]. The respective amino acid sequences and their alignments to the corresponding HSV-1 homologs are displayed in Figure 2. Protein gB shares 79.0% sequence identity with its HSV-1 homolog and 80.4% with that of HSV-2. For gD the corresponding values are 57.0% and 59.0%, respectively [2].

Sequences of 422 pentadecapeptides were designed to cover gB and gD of herpes B in an overlapping fashion (Figure 1). The peptides were prepared by ‘Spot-Synthesis’ [9] and printed onto glass slides [10]. The resulting microarray chips were used to analyze antibody spectra of rhesus macaque sera (6 references and 36 test samples).

In brief, chips were incubated with diluted macaque serum, followed by incubation with a cross-reactive secondary antibody (anti-human IgG) conjugated to a fluorescent dye. A standard chip reader was used for signal detection. Unprocessed readings (i.e. data as provided by the instrument as TIF files) were inspected visually, then analyzed numerically by a computed ‘spot calling’ algorithm described under Materials and Methods. All assignments of a positive or negative response to an individual array spot followed the output of this algorithm.

General Features of Primary Data

Application of a large set of sera from rhesus macaques resulted in a variety of positive signals on the microarray slides. Representative raw data obtained with sera from different animals are outlined in Figure 3. Sera represented in the majority of cases by an isolated single spot (numbered ‘7’ in Figure 3 A, D; compare to E). This exception is dealt with in detail below (see “Mapping ATRs to the three-dimensional structures of gB”). Overall, sera that were tested positive in the HSV-ELISA (Table 1) typically responded with several spot series on the peptide microarray. Response spectra of individual sera, while having some overlap, differed from one another.

According to the experimental design, a consecutive series of positive spots represents the binding area of a single or multiple antibodies that are present in the serum. The epitope length becomes smaller with increasing number of positive spots and, under the chosen regime of tiling pentadecapeptides with a progression of three amino acid residues per step, the maximal number of spots in one series is five. Since distinct antibodies can contribute to one spot series we use the term ‘antibody target region’ (ATR).

Synopsis of Total Data Set

A total of 42 sera were investigated. Columns marked “1” to “18” in Table 1 list contributions of different ATRs to a total of 114 individual positive reactions. With 63 responses elicited by gB and 51 by gD, the two proteins are of comparable antigenicity, at least with regard to the detected linear epitopes. The study is grounded in six reference sera obtained from an external source (see Materials and Methods) and pre-marked by the supplier as...
The 36 test sera derived from different rhesus macaque breeding groups which had been known to include carriers of herpes B. By the HSV-ELISA criterion, 30 test sera were classified as positive, six as negative. In the parallel chip assay, one of the HSV-ELISA-positive sera (sample 33) did not respond to any of the 18 gB and gD ATRs; likewise, in the HSV-ELISA-negative group, one serum (sample 42) elicited a positive response on the chip (ATR15). In all other cases the results of one assay matched that of the other.

Response Statistics

The 114 positive ATR responses are distributed unequally among sera derived from 34 macaques (HSV-ELISA-positive subset plus sample 42) corresponding to an average of 3.4 ATRs per serum. The distribution around this mean value is illustrated in Figure 5, panel A. The number of occurrences of individual ATRs is conspicuously different, varying between one (ATR1, 4, 6, 13, 15 and 17 and 42) and 26 (ATR18). The complete spectrum of occurrences is shown in Figure 5, panel B. Of note, ATR18 was detected in 79% of all tested sera reacting with gD which is in the same range as reported [8]. Interestingly, we also found that in five ATR18-positive sera, the response was limited to peptides representing amino acid sequence immediately following the TM-domain (Table 2) and not extending into the previously described epitope [8].

In the HSV-ELISA-positive subset (33 sera), there are nine samples without a gB response (27%). The respective number for gD is five (15%). Under the assumption of such response failures occurring independently, the expected rate of double failures amounts to 4%. There is, indeed, one case (sample 33) in which an HSV-ELISA-positive sample failed to react with any peptide derived from either gB or gD, which corresponds to a double failure rate of 3%. This discrepancy between HSV-ELISA and herpes B-specific peptide microarray could be attributable to antibodies directed against discontinuous or glycosylated epitopes or glycoproteins other than gB or gD. In one case we detected one positive response in the peptide microarray (ATR15/serum sample #42), while the same serum was tested negative by HSV-ELISA. Whether this represents a 'false negative' in HSV-ELISA or 'false-positive' result in the chip assay cannot be judged, unless proven by a third independent method.

Mapping ATRs to the Three-dimensional Structure of gB

*Simplexvirus* glycoprotein B is an integral membrane protein, anchored in the viral envelope with one membrane-spanning domain [13]. While no direct structural information is available for herpes B gB, the three-dimensional structure of a soluble ectodomain fragment of its closely related HSV-1 homolog has been determined by x-ray crystallography [14]. According to the sequence alignment (Figure 2), four out of 11 ATRs (#4, 5, 6 and 7) of herpes B gB identified in this present study map within the crystallized HSV-1 fragment. Projection of the four ATRs onto the crystal structure revealed that they were located on the protein surface (Figure 6).

A response to ATR6 was observed only once in the entire study (sample 20, Table 1) whereas antibodies directed against ATR7 were detected in ten sera (Figure 5, panel B; Table 1). There are two classes of ATR7 response: In one case (sample 4, Figure 3E) two peptides (array spots #196 and #197) were detected, together defining an ATR length of 18 residues as indicated in Figure 2 and Table 3. In the other nine cases, the ATR7 response was restricted to a single responding peptide (#197; Figure 3A and D), a result formally implying an epitope comprising 15 amino acid residues.
Table 1. Distribution of individual ATRs in sera of 42 different macaques.

| Sample No.* | Antibody target region | HSV-ELISA |
|-------------|------------------------|-----------|
|             | glycoprotein B          | glycoprotein D |
| 1           |                        |               |
| 2           | X                      | X pos.       |
| 3           | X                      | X pos.       |
| 4           | X X                    | X pos.       |
| 5           | X X                    | X pos.       |
| 6           | X                      | X X X X pos. |
| 7           | X X                    | X pos.       |
| 8           | X                      | X X X X pos. |
| 9           | X X                    | X X pos.     |
| 10          | X X                    | X pos.       |
| 11          | X X                    | X pos.       |
| 12          | X X                    | X pos.       |
| 13          | X X                    | X pos.       |
| 14          | X X                    | X pos.       |
| 15          | X X                    | X pos.       |
| 16          | X                      | X X X pos.   |
| 17          | X                      | X X pos.     |
| 18          | X                      | X pos.       |
| 19          | X                      | X pos.       |
| 20          | X X                    | X pos.       |
| 21          | X X                    | X pos.       |
| 22          | X                      | X pos.       |
| 23          | X X                    | X pos.       |
| 24          | X                      | X pos.       |
| 25          | X X                    | X pos.       |
| 26          | X                      | X pos.       |
| 27          | X X                    | X pos.       |
| 28          | X                      | X pos.       |
| 29          | X                      | X pos.       |
| 30          | X                      | X pos.       |
| 31          | X                      | X pos.       |
| 32          | X                      | X pos.       |
| 33          |                        | pos.        |
| 34          |                        | neg.        |
| 35          |                        | neg.        |
| 36          |                        | neg.        |
| 37          |                        | neg.        |
| 38          |                        | neg.        |
| 39          |                        | neg.        |
| 40          |                        | neg.        |
| 41          |                        | neg.        |
| 42          |                        | X           |

*Serum samples were obtained in 2010 from rhesus macaques kept at the German Primate Center. Responses to particular ATRs are indicated (X). Column designated "HSV-ELISA": Results of HSV-ELISA assay (Figure 4).
1 Results after affinity enrichment of IgG using protein A (samples of crude sera produced high background).
2 Results from serum of the same animal retrieved in 2008 (sample of 2010 produced high background). Numbers of positive (1–3) and negative sera (34–36) are given in bold; source: National B Virus Resource Laboratory, Atlanta, GA, USA.

doi:10.1371/journal.pone.0086857.t001
Figure 3. Graphical representation of results obtained with six different sera (single array enlargements). A is sample #11; B, #21; C, #16; D, #15; E, #4; F, #42. White frames indicate array spots identified as positive by the spot calling algorithm.

doi:10.1371/journal.pone.0086857.g003

Figure 4. Graphical representation of results obtained with modified commercial anti-HSV ELISA. In total 42 serum samples were analyzed. The black bars indicate positive (samples 1–3) and negative (samples 34–36) references; Source: National B Virus Resource Laboratory, Atlanta, USA. Open bars represent samples derived from the DPZ rhesus macaque breeding groups. The cut-off value was defined as twice the value of the reaction of the negative reference sample (#34) yielding the highest O.D. among the three negative reference samples and is indicated by a horizontal line. Sera were tested at a 1:200 dilution. Standard deviations (SD) of duplicate measurements are indicated.

doi:10.1371/journal.pone.0086857.g004
Mapping ATRs to the Three-dimensional Structure of gD

Like gB (compare above), *Simplexvirus* gD is anchored in the viral envelope by a single membrane-spanning domain [15]. The three-dimensional structure of a soluble fragment of HSV-1 gD (“gD306rots”, PDB number 2C36, chain A) has been determined by x-ray crystallography [15]. Of the seven ATRs of herpes B gD detected by serological chip assay, ATR18 is not contained in the crystallized fragment; ATR12 as well as the 10 aminoterminal residues of ATR16 and the 10 carboxyterminal residues of ATR17 are located in regions of ill-defined electron density [15]. Guided by sequence alignment, remaining ATR13, 14, and 15 and the 20 most carboxyterminal residues of ATR16 and the 11 most aminoterminal residues of ATR17 can be projected onto the three-dimensional structure of HSV-1 gD as illustrated in Figure 7.

ATR17 makes up the C-terminus of the ordered polypeptide chain (blue in Figure 7) and is packed crosswise on top of ATR13 (N-terminus of ordered chain, yellow in Figure 7). Both together form the crest of a protrusion from the gD molecules while ATR13, 14 and 15 contribute solvent-exposed areas on both of its flanks - with concomitant hiding of substantial parts of ATR sequence in the interior. A possible explanation for this is offered by assuming that, in the natural situation, alternative structures are available to the domain termini in which areas seen as buried in the crystal are (transiently?) exposed and made accessible for interaction with B cell receptors. This kind of structural flexibility of the chain segments under consideration has been invoked earlier in connection with binding of gD to infection-relevant host receptors [15,16]. In particular, contacts of gD to bound nectin-1 [16] involve extensive surface area of ATR15 buried in the closed conformation. Of note, in Figure 7, N and C do not represent true physical chain termini [15].

### Discussion

Prior to our study, only one epitope had been mapped to a defined site within any antigen of herpes B [8]. In contrast, scanning a few dozens of monkey sera with a tiled peptide microarray representing glycoproteins gB and gD was sufficient to identify and precisely locate 18 ATRs within these two polypeptides. Several ATRs of gD cluster in a locally confined region of the protein surface with obviously high antigenicity. In the chip assay, macaque sera reacting uniformly positive in HSV-ELISA individually responded to strikingly different, fingerprint-like subsets of the 18 ATRs.

Immuneological Impact of ATR Distribution

Although the majority of the identified ATRs are located on the outside of the glycoproteins, some ATRs are likely located on the inner side of the viral envelope amounting to 33% of all individual ATR-directed responses. This effect is particularly pronounced for ATR18, which alone accounts for ~79% of all individual responses mapping to gD. This is in agreement with an earlier study that had identified the nine most carboxyterminal residues of gD as an immunodominant B cell epitope in rhesus macaques – hitherto the only one mapped to a specific position within an antigen of herpes B [8]. While antibodies directed against targets hidden inside a closed membrane are a rather common phenomenon, it is not clear how they arise.

For a protein like gD, with a single membrane-spanning domain and a short cytosolic tail, reversible switching of membrane topology as reported for HBV from TM1 to TM3 [17], thereby exposing parts of the endodomain is very unlikely. Still, ATR18 is highly antigenic but, significantly, it does not elicit neutralizing antibodies [8]. By comparison, the existence of neutralizing antibodies directed against the so-called Kennedy epitope of HIV-1 has been used as an argument supporting a topology switch of the much larger gp41 cytosolic tail [18–20]. The same issue has additionally been discussed in connection with the cytosolic tail of SIV gp41 and put in relation with other known cases [21].

The ectodomain of gB contains a conspicuously large gap devoid of ATRs. This is true for both amino acid sequence (compare e.g. Figure 2A, gap between ATR4 and ATR5) and the three-dimensional structure (Figure 6). Protein glycosylation is a plausible candidate for causing these gaps. Almost all known glycosylation sites of HSV-1 gB and gD are located outside the ATRs found during this present study [22,23]. This may be due to two different, mutually non-exclusive reasons: (i) antibodies directed against glycosylated sites may be present in the serum but not able to bind to the corresponding nonglycosylated peptides on the chip; (ii) glycans may shield surrounding areas of the protein from docking of B cell receptors [24].

---

### Table 2. Break down of individual responses to ATR18 in monkey sera.

| Sample No. | Spot No. | 507 | 508 | 509 | 510 | 511 | 512 |
|------------|----------|-----|-----|-----|-----|-----|-----|
| 1          |          | X   | X   |     |     |     |     |
| 2          |          | X   | X   | X   |     |     |     |
| 3          |          |     | X   | X   |     |     |     |
| 4          |          | X   | X   | X   | X   |     |     |
| 5          |          |     |     |     |     |     |     |
| 6          |          |     |     |     | X   | X   |     |
| 7          |          | X   | X   | X   | X   | X   | X   |
| 8          |          | X   | X   |     |     |     |     |
| 9          |          |     |     |     | X   | X   | X   |
| 10         |          |     |     |     |     |     | X   |
| 11         |          | X   | X   | X   | X   |     |     |
| 12         |          |     |     |     |     | X   |     |
| 13         |          | X   |     |     |     |     |     |
| 14         |          |     |     |     |     |     |     |
| 15         |          | X   |     |     |     |     |     |
| 16         |          |     |     |     |     |     |     |
| 17         |          |     |     |     |     |     | X   |
| 18         |          | X   | X   | X   | X   |     |     |
| 19         |          |     |     |     | X   | X   | X   |
| 20         |          |     |     |     |     |     | X   |
| 21         |          |     |     |     | X   |     | X   |
| 22         |          | X   | X   | X   |     |     |     |
| 23         |          |     |     |     |     | X   |     |
| 24         |          | X   |     |     |     |     |     |
| 25         |          |     |     |     |     | X   | X   |
| 26         |          |     |     |     |     |     | X   |
| 27         |          |     |     |     |     |     | X   |
| 28         |          |     |     |     |     |     | X   |
| 29         |          | X   | X   | X   |     |     |     |
| 30         |          |     |     |     |     |     | X   |
| 31         |          |     |     |     |     |     | X   |
| 32         |          |     |     |     |     |     | X   |

Antibody binding with single peptides of ATR18 on the peptide microarray are indicated (X).
doi:10.1371/journal.pone.0086857.t002
Comparison of the here described ATRs in herpes B with published linear epitopes of HSV-1 and -2 [25,26] reveals that some antigenic regions are very similar between these closely related viruses. As outlined in Table S1, linear epitopes that were described for HSV partially or completely overlap with ATRs 2, 3, 5, 12, 16 and 17. However, at least some of these lack high sequence similarity. For example, ATR2 completely overlaps with the known HSV gB epitope H1817 [26], but only 6 out of 13 amino acid residues are identical (Table S1). This might indicate that the structural position of this linear epitope is responsible for its immunogenicity rather than the primary amino acid sequence. Another factor contributing to different epitope patterns may be the divergent immune response of humans versus non-human primates.

Structure of Peptide #197

As mentioned under Results, spot #197 represents an antibody target of 15 amino acid residues formal length located at the C-terminal end of ATR7. This has to be attributed to a single epitope since a single responding spot implies that removal of three amino acid residues from either end of the 15mer leads to complete loss of binding – and this is incompatible with the notion of a target region composed of two or more distinct epitopes. On the other hand, it seems difficult to imagine how that much polypeptide chain could be accommodated in the antigen binding pocket of a typical antibody. The location of ATR7 at the surface of gB (Figure 6) lends additional credibility to its being a true B cell epitope, but a convincing structural explanation is lacking. Intriguingly, the sequence stretch corresponding to peptide #197 (V589 - Q603) coincides with a β-hairpin resting on or protruding from the gB surface (Figure 6). The interior of the ATR7 sequence (i.e. the loop of the hairpin) could be irrelevant for antibody binding but the critical contacting residues be distributed among the two strands of the β-hairpin – well separated along the chain but close neighbors in space. Any shortening of peptide #197, at either end, would remove such critical residues and lead to loss of antibody binding. Alternatively, the critical residues could reside within a continuous stretch of loop sequence but the antibody binding depends upon a particular chain conformation requiring the structural context of the β-hairpin. Formation of the latter would, in turn, be sensitive against any shortening of either of the two β-strands. As a corollary of the above, ATR7 emerges as a highly antigenic region in a special sense: It seems to elicit, with high selectivity (nine out of ten cases), antibodies that are conformation-dependent in one of two possible ways sketched above.

Diagnostic Implications

Mapping anti-herpes B antibody targets may be a valuable tool to assist or confirm current HSV-ELISA based diagnostics of herpes B. Taking HSV-ELISA results as a reference, the peptide microarray chip assay produced 27% false negatives for gB and 15% for gD. The observed number of double failures was one – in accord with prediction made on the premise of gB and gD false negatives occurring independently. On this basis, a crude estimate can be made of the extent by which the rate of false negative
Figure 6. Alignment-guided mapping of four ATRs to the three dimensional structure of an HSV-1 gB ectodomain fragment trimer (PDB number 3NWA chain A residues D103 to A730). Compared to the unprocessed translation product described in Figure 2A, the crystallized fragment lacks the 102 N-terminal residues plus the entire C-terminal part (residues 731–904 spanning the carboxyterminal end of the ectodomain: residues 731–773, the transmembrane region: residues 774–795 and the endodomain: residues 796–904). Within the crystallized fragment, there are two stretches of disordered chains (residues 477–491 and 724–730 [14]). Panel A shows the molecule in ribbon representation and panel B as solvent-accessible surface. ATR4 sequence (7 most carboxyterminal residues) is shown in red, ATR5 (14 N-terminal residues) in blue, ATR6 sequence (eleven most carboxyterminal residues) is highlighted in cyan and ATR7 in green. The ribbon representation of ATR7 is magnified in the inset to emphasize the \( b \)-hairpin corresponding to spots \#196 and197 of the peptide microarray. doi:10.1371/journal.pone.0086857.g006

| ATR   | Spot no. | aa position | Sequence | aa length |
|-------|----------|--------------|----------|-----------|
| glycoprotein B | 1 | 2–3 | 4–21 | RAGPLPLPSPLVLLALA | 18 |
| | 2 | 10–14 | 28–54 | PLGPAAATPVPSRIPPSPAVPVPAATPT | 27 |
| | 3 | 16–21 | 46–75 | PPVPAAATPSDDNQGEAGAPGTNA | 30 |
| | 4 | 26–28 | 76–96 | SVEAGHIATLIREIKDIKALKGD | 21 |
| | 5 | 151–154 | 451–474 | YVRELLRQERRPGDAAATPKPSA | 24 |
| | 6 | 157–159 | 469–489 | TPKPSADPDVQKKTTSVE | 21 |
| | 7 | 196–197 | 586–603 | RPLVSRFEEGGPVLEGQ | 18 |
| | 8 | 239–242 | 715–738 | HAALFAGLYSGFEGLGVDGRAVGK | 24 |
| | 9 | 273–275 | 817–837 | DGASGGGEGEDEAKLAQARE | 21 |
| | 10 | 284–288 | 850–876 | RTEHARKKGTSSLASSKTVNMVRXK | 27 |
| | 11 | 292–294 | 874–892 | RKRRAKPRYSLPGDOTDEEL | 19 |
| glycoprotein D | 12 | 392–396 | 22–48 | GGGEYVPERSLTVRNGRFRGAHLAP | 27 |
| | 13 | 401–402 | 49–66 | LEQKTDPPDVRVYVHYQP | 18 |
| | 14 | 436 | 154–168 | VRNLPRWFSFYDNFGA | 15 |
| | 15 | 465–466 | 244–258 | GIGLPRFIPENQRIVAV | 18 |
| | 16 | 479–484 | 283–312 | VETANATRPELEDQEDPGDEPAVA | 30 |
| | 17 | 492–494 | 322–342 | PEASDVQIPAPAPSGHTGA | 21 |
| | 18 | 507–512 | 367–394 | RARAAKHKVRLPHELDEGPGPAARGFY | 28 |
results could be brought down further by incorporating additional antigens, e.g. gC and gD [4]. It can be calculated that with 12 relevant ATRs per antigen, a test based on less than 50 different peptides could bring the frequency of false negatives down to the range of one in a thousand. Since this number of peptides is manageable, a peptide ELISA- or bead-based diagnostic test could be developed as an alternative to possibly cost-limiting peptide microarrays.

Limitations of the Method

Microarrays of tiled peptides delineating total amino acid sequences of relevant antigens are excellent tools to determine, in a single simple experiment, the entire spectrum of linear epitopes of that antigen recognized by antibodies populating a specific individual serum. As already mentioned above, glycosylation-specific antibodies will be missed as long as the microarrays do not include relevant peptide-glycan conjugates. The same is true for other post-translational protein modifications such as phosphorylation, acetylation and methylation. Furthermore, discontinuous epitopes will be missed. Solutions suggested in the literature [27,28] include chips displaying binary combinatorial libraries of antigen fragments and of peptides conformationally constrained by cyclization. A more general solution to the above problems might be offered by replacing antigen-specific scanning chips by arrays of large numbers of peptides of random sequence.

Outlook

The data documented and discussed above reinforce the unique usefulness of synthetic peptide microarray chips in characterizing antibody spectra at the level of individual epitopes or ATRs. Clearly, the potential of the method reaches beyond mere factual assessment of viral infections into direct and detailed visualization of individual humoral immune responses mounted against a pathogen or vaccine with potentially profound consequences for therapy, prognosis and monitoring vaccination or therapeutic success. Moreover, work in progress in our laboratories endorses high resolution chip serology as a tool for gleaning insight on issues of fundamental biological and medical importance such as viral multiplication, latency and escape.
Supporting Information

Table S1 Comparison of antibody target regions (ATRs) in glycoprotein B and D of herpes B virus with known epitopes of herpes simplex virus (HSV).

Acknowledgments

We thank Julia K. Hilliard and Marty Wildes, National B Virus Resource Center, Georgia State University, Atlanta, Georgia, USA for providing herpes B reference sera and Gabriela Salmans-Riester, DNA Microarray Facility, University Medical Center, Göttingen, Germany, for granting access to an Agilent microarray scanner and helpful technical support. Georgia Hesse provided excellent technical assistance.

We also thank Frank Hufert for taking continuous interest in the project and by offering the hospitality of his laboratory.

Author Contributions

Conceived and designed the experiments: DJ RF GH CS JJF SKH DM AA. Performed the experiments: SKH AA UB. Analyzed the data: SKH AA UB DJ RM GH CS JJF. Contributed reagents/materials/analysis tools: SKH RF RM UB CS JJF. Wrote the paper: SKH AA DM GH CS JJF. Critical revision: SKH AA UB DM RF GH CS JJF.

References

1. Sahin AR, Wright AM (1934) Acute ascending myelitis following a monkey bite, with the isolation of a virus capable of reproducing the disease. J Exp Med 59: 115–136.
2. Perelygina L, Zhu L, Zurkuhlen H, Mills R, Borodovsky M, et al. (2003) Complete sequence and comparative analysis of the genome of herpes B virus (Cercopithecine herpesvirus 1) from a rhesus monkey. J Virol 77: 6167–6177.
3. Jankitiwong A, Langlais RP (1998) Herpes B virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 399–403.
4. Elmore D, Eberle R (2008) Monkey B virus (Cercopithecine herpesvirus 1). Comp Med 58: 11–21.
5. Perelygina L, Patrušova I, Hombaiah S, Zurkuhlen H, Wildes MJ, et al. (2005) Production of herpes B virus recombinant glycoproteins and evaluation of their diagnostic potential. J Clin Microbiol 43: 620–628.
6. Morton WR, Agy MB, Capuano SV, Grant RF (2008) Specific pathogen-free macaques: definition, history, and current production. ILAR J 49: 137–144.
7. Coulthab C, Hack R, Scidl J, Chudy M, Iter G, et al. (2004) A natural asymptomatic herpes B virus infection in a colony of laboratory brown capuchin monkeys (Cebus apella). Lab Anim 38: 492–498.
8. Perelygina L, Zurkuhlen H, Patrušova I, Hilliard JK (2002) Identification of a herpes B virus-specific glycoprotein d immunodominant epitope recognized by natural and foreign hosts. J Infect Dis 186: 453–461.
9. Frank K (1992) Spot-synthesis - an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48: 9217–9232.
10. Dikmans A, Beutling U, Schmeisser E, Thiele S, Frank R (2006) SC2: A novel process for manufacturing multipurpose high-density chemical microarrays. QuaR & Combinatorial Science 25: 1069–1080.
11. Schneider CA, Rashand WS, Elciiri KW (2012) NIH Image to Imagej: 25 years of image analysis. Nat Methods 9: 671–675.
12. Perelygina L, Patrušova I, Zurkuhlen H, Hilliard JK (2002) Characterization of B virus glycoprotein antibodies induced by DNA immunization. Arch Virol 147: 2057–2073.
13. Gilbert R, Ghosh K, Rasile L, Ghosh HP (1994) Membrane anchoring domain of herpes simplex virus glycoprotein gD is sufficient for nuclear envelope localization. J Virol 68: 2272–2285.
14. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, et al. (2006) Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313: 217–220.
15. Krümmeneracher C, Supelak VM, Whitbeck JC, Lazzar E, Connolly SA, et al. (2005) Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J 24: 4144–4153.
16. Di Giovine P, Settembre EC, Bhargava AK, Luftig MA, Lou H, et al. (2011) Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog 7: e1002277.
17. Bruss V (2007) Hepatitis B virus morphogenesis. World J Gastroenterol 13: 65–73.
18. Helleur MJ, Dinnock NJ (2005) The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function. Virology 337: 294–296.
19. Steckbeck JD, Kuhlmann AS, Montelaro RC (2013) C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Virol 94: 1–19.
20. Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC (2010) Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS One 5: e15261.
21. Poulet TS, Martinez-Navio JM, Yuste E, Desrosiers RC (2012) Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J Virol 86: 1145–1157.
22. Wang J, Fan Q, Satoh T, Ari J, Lanier LL, et al. (2009) Binding of herpes simplex virus glycoprotein B (gB) to paired immunoglobulin-like type 2 receptor alpha depends on specific sialylated O-linked glycans on gB. J Virol 83: 13042–13045.
23. Sodora DL, Cohen GH, Eisenberg RJ (1989) Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D. J Virol 63: 5184–5193.
24. Vigerust DJ, Shepherd VL (2007) Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 15: 211–218.
25. Lazzar E, Whittbeck JC, Ponce-de-Leon M, Caimi TM, Willis SH, et al. (2012) Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization. J Virol 86: 1563–1576.
26. Bender FC, Samanta M, Heldwein EE, de Leon MP, Binman E, et al. (2007) Antigenic and mutualional analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol 81: 3827–3841.
27. Tzimoneras P, Beld J, Puijk WC, Meloen RH (2005) Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem 6: 821–824.
28. Tzimoneras P, Van Dijk E, Puijk W, Schaper W, Skoutera J, et al. (2004) Mapping of a discontinuous and highly conformational binding site on follicle stimulating hormone subunit-beta (FSH-beta) using domain Scan and Matrix Scan technology. Mol Divers 8: 61–77.